IRVINE, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. today announced that the company will be presenting at six investor and partnering conferences in the United States and abroad during the month of November as part of its strategy to keep investors and key stakeholders around the world updated on Spectrum’s progress. At these conferences, the company will present a corporate overview of the company and its development programs.
The conference information is as follows: * Rodman & Renshaw 8th Annual Healthcare Conference. Presentation: Monday, November 6, 2006 at 12:05 p.m. Eastern Time (9:05 a.m. Pacific Time) at the Palace Hotel in New York City. Russell Skibsted, Senior Vice President and Chief Business Officer of Spectrum will present. This presentation will be webcast. * PharmaVenue. Presentation: Monday, November 6, 2006 at 4:30 p.m. Central European Time (7:30 a.m. Pacific Time) at the Princesa Sofia Hotel in Barcelona, Spain. Rajesh C. Shrotriya, M.D., Chairman, Chief Executive Officer and President of Spectrum will present. This presentation will not be webcast. * BIO-Europe 2006. Presentation: Tuesday, November 7, 2006 at 2:00 p.m. Central European Time (5:00 a.m. Pacific) at the Congress Center in Dusseldorf, Germany. Rajesh C. Shrotriya, M.D., Chairman, Chief Executive Officer and President of Spectrum will present. This presentation will not be webcast. * BIOCOM San Diego Investor Conference. Presentation: Wednesday, November 15, 2006 at 4:20 p.m. Pacific Time at the San Diego Marriott Hotel in Del Mar, California. William Pedranti, Vice President, General Counsel will present. This presentation will not be webcast. * Southwestern Showcase Investor Conference. Presentation: Thursday, November 16, 2006 at 10:50 a.m. Central Time (8:50 a.m. Pacific Time) at the Hilton Hotel in Dallas. Russell Skibsted, Senior Vice President and Chief Business Officer of Spectrum will present. This presentation will not be webcast. * Lazard Capital Markets Third Annual Life Sciences Conference. Presentation: Wednesday, November 29, 2006 at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time) at the Palace Hotel in New York City. Rajesh C. Shrotriya, M.D., Chairman, Chief Executive Officer and President of Spectrum will present. This presentation will be webcast.
The presentations that will be webcast will be available under the investor relations section of Spectrum’s website at http://www.spectrumpharm.com. Replays of the presentations will be available for 30 days following the event. Please connect to Spectrum’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals opportunistically acquires and advances a diversified portfolio of drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum’s expertise lies in identifying undervalued drug candidates with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company’s pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. For more information, please visit our website at www.spectrumpharm.com.
Forward-looking statements
This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum’s ability to identify, acquire and develop its portfolio of drug candidates, the Company’s promising pipeline, expanding our investor base and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that past results may not be indicative of future results, the possibility that price and other competitive pressures may make the marketing and sale of our generic drugs not commercially feasible, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of significant revenues, our limited human and financial resources, our limited experience in establishing strategic alliances, our limited marketing experience, our limited experience with the generic drug industry, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company’s reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
Media Susan Neath Porter Novelli Life Sciences (619) 849-6007 Raj Shrotryia President & CEO Spectrum Pharmaceuticals (949) 743-9295 Russell Skibsted SVP & Chief Business Officer Spectrum Pharmaceuticals (949) 743-9234
Spectrum Pharmaceuticals, Inc.
CONTACT: Media, Susan Neath of Porter Novelli Life Sciences,+1-619-849-6007, for Spectrum Pharmaceuticals, Inc.; or Raj Shrotryia,President & CEO, +1-949-743-9295, or Russell Skibsted, SVP & Chief BusinessOfficer, +1-949-743-9234, both of Spectrum Pharmaceuticals
Web site: http://www.spectrumpharm.com/
